TRICIN: A Phase II Trial on the Efficacy of Topical TRIchloroacetic Acid in Patients with Cervical Intraepithelial Neoplasia

SIMPLE SUMMARY: Roughly, 5% of all women undergoing screening for cervical cancer suffer from cervical intraepithelial neoplasia (CIN). Persistent and high grade CIN are usually treated by conization. Conization is associated to several long-term complications such as preterm deliveries. Therefore,...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwameis, Richard, Ganhoer-Schimboeck, Julia, Hadjari, Victoria Laudia, Hefler, Lukas, Bergmeister, Birgit, Küssel, Tatjana, Gittler, Gunda, Steindl-Schoenhuber, Theodora, Grimm, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9740961/
https://www.ncbi.nlm.nih.gov/pubmed/36497473
http://dx.doi.org/10.3390/cancers14235991
Descripción
Sumario:SIMPLE SUMMARY: Roughly, 5% of all women undergoing screening for cervical cancer suffer from cervical intraepithelial neoplasia (CIN). Persistent and high grade CIN are usually treated by conization. Conization is associated to several long-term complications such as preterm deliveries. Therefore, non-surgical treatment approaches to CIN are urgently needed. Up to now only retrospective data were available for the topical treatment with trichloroacetic acid (TCA). This is the first prospective trial showing high efficacy of TCA in the treatment of CIN. In the future, TCA may represent an effective and feasible non-surgical treatment approach for CIN. ABSTRACT: Data on non-surgical treatment approaching persistent cervical intraepithelial neoplasia (CIN) are scarce. Retrospective analysis suggest high efficacy of topical treatment with trichloroacetic acid (TCA). This prospective phase II study set out to investigate the efficacy of a single application of 85% TCA in the treatment of CIN I/II. Patients with CIN I/II were treated a single time with 85% TCA. After three and six months colposcopic, histologic, and HPV evaluation was performed. The primary endpoint was treatment efficacy defined as complete histologic remission six months after treatment. The secondary endpoint was HPV clearance six months after treatment. A total of 102 patients with CIN I/II were included into this trial. Complete histologic remission rates were 75.5% and 78.4% three and six months after TCA treatment, respectively. Clearance rates of HPV 16, 18 and other high risk types were 76.5%, 91.7%, 68.7% after six months, respectively. Side effects of TCA were mild and lasted usually less than 30 min. This is the first prospective trial reporting high histologic complete remission rates in patients with CIN I/II after a single 85% TCA treatment. In the future, TCA may represent an effective and feasible non-surgical treatment approach for CIN.

Ejemplares similares